Trial reportThe Journal of infectious diseases2014
Impact of vancomycin on sarA-mediated biofilm formation: role in persistent endovascular infections due to methicillin-resistant Staphylococcus aureus.
Trial report in The Journal of infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 82 citations in OpenAlex.
- Auranofin potentiates linezolid activity against MRSA by disrupting redox homeostasis and inhibiting SarA-mediated virulence and biofilm.Virulence · 2026Article
- CRISPR-driven strategies to disrupt methicillin-resistantFrontiers in cellular and infection microbiology · 2026Review
- Phage-Encoded Virulence Factor, Gp05, Alters Membrane Phospholipids and Reduces Antimicrobial Susceptibility in Methicillin-Resistant Staphylococcus aureus.The Journal of infectious diseases · 2025Article
- Pharmacological strategies for targeting biofilms in otorhinolaryngologic infections and overcoming antimicrobial resistance (Review).Biomedical reports · 2025Review
- Early cytokine signatures and clinical phenotypes discriminate persistent from resolving MRSA bacteremia.BMC infectious diseases · 2025Article
- Prophage ϕSA169 Enhances Vancomycin Persistence in Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Proteomics and acetyl-proteomics reveal the antibacterial mechanism of berberine sulfate against methicillin-resistantFrontiers in microbiology · 2025Article
- Combating multidrug-resistant (MDR) Staphylococcus aureus infection using terpene and its derivative.World journal of microbiology & biotechnology · 2024Review
- Adaptive physiological and metabolic alterations in Staphylococcus aureus evolution under vancomycin exposure.World journal of microbiology & biotechnology · 2024Article
- Restriction of arginine induces antibiotic tolerance in Staphylococcus aureus.Nature communications · 2024Article
- Effect of gallium nitrate on the antibacterial activity of vancomycin in methicillin-sensitive and resistant Staphylococcus aureus.Archives of microbiology · 2024Article
- The Purine Biosynthesis Repressor, PurR, Contributes to Vancomycin Susceptibility of Methicillin-resistant Staphylococcus aureus in Experimental Endocarditis.The Journal of infectious diseases · 2024Article
- Effects of sub-inhibitory concentrations of nafcillin, vancomycin, ciprofloxacin, and rifampin on biofilm formation of clinical methicillin-resistantMicrobiology spectrum · 2024Article
- Cinnamaldehyde targets SarA to enhance β-lactam antibiotic activity against methicillin-resistantmLife · 2024Article
- Sensitizing methicillin-resistantAntimicrobial agents and chemotherapy · 2024Article
- Sub-inhibitory concentrations of ceftriaxone induce morphological alterations and PIA-independent biofilm formation in Staphylococcus aureus.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Effects of Vancomycin Subtherapeutic Concentration on Staphylococcus aureus Isolated from Hemodialysis Patients with Low Serum Trough Concentrations.Current microbiology · 2024Article
- Quercetin targets SarA of methicillin-resistantMicrobiology spectrum · 2024Article
- Gp05, a Prophage-Encoded Virulence Factor, Contributes to Persistent Methicillin-Resistant Staphylococcus aureus Endovascular Infection.Microbiology spectrum · 2023Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundStaphylococcus aureus is the most common cause of endovascular infections. The staphylococcal accessory regulator A locus (sarA) is a major virulence determinant that may potentially impact methicillin-resistant S. aureus (MRSA) persistence in such infections via its influence on biofilm formation.
methodsTwo healthcare-associated MRSA isolates from patients with persistent bacteremia and 2 prototypical community-acquired MRSA strains, as well as their respective isogenic sarA mutants, were studied for in vitro biofilm formation, fibronectin-binding capacity, autolysis, and protease and nuclease activities. These assays were done in the presence or absence of sub-minimum inhibitory concentrations (MICs) of vancomycin. In addition, these strain pairs were compared for intrinsic virulence and responses to vancomycin therapy in experimental infective endocarditis, a prototypical biofilm model.
resultsAll sarA mutants displayed significantly reduced biofilm formation and binding to fibronectin but increased protease production in vitro, compared with their respective parental strains. Interestingly, exposure to sub-MICs of vancomycin significantly promoted biofilm formation and fibronectin-binding in parental strains but not in sarA mutants. In addition, all sarA mutants became exquisitely susceptible to vancomycin therapy, compared with their respective parental strains, in the infective endocarditis model.
conclusionsThese observations suggest that sarA activation is important in persistent MRSA endovascular infection, potentially in the setting of biofilm formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.